HighTower Advisors
PRVL

HighTower Advisors’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

HighTower Advisors’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,130,000
Closed -$11.5M – 3044
2020
Q3 		$11.5M Buy
+1,130,000
New +$15.2M 0.06% 310

Other funds holding PRVL

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Boxer Capital
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alpine Associates Management
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TIG Advisors LLC
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HighTower Advisors's PRVL Position: Q4 2020 in Review

HighTower Advisors sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020, closing a stake of 1,130,000 shares — an estimated $11.5M sold.

HighTower Advisors first reported a position in PRVL in Q3 2020 and held it in 1 quarter. The position peaked at $11.5M in Q3 2020. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

  • HighTower Advisors reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • HighTower Advisors sold 1,130,000 Prevail Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $11.5M.
  • HighTower Advisors first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • HighTower Advisors's Prevail Therapeutics Inc. Common Stock position peaked at $11.5M in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on HighTower Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.